Myasthenia Gravis

More than half of the young patients with myasthenia gravis (MG) responded well to the use of corticosteroids.

Empathy, knowledge, and attitudes in care for patients with myasthenia gravis were improved when using a patient-centric immersive virtual reality intervention.

A review of case studies found that patients with double seronegative myasthenia gravis (MG) had similarities in the ways their condition presented.

Minimizing the use of corticosteroids in clinical practice can help to prevent any long-term impact on patients with myasthenia gravis.

Methylprednisolone was more effective in treating thymoma compared with docetaxel but adverse effects were more common.

Patients with myasthenia gravis experience significantly higher rates of urinary incontinence and overactive bladder symptoms, impacting their quality of life.

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Patients with generalized myasthenia gravis face significant barriers to diagnosis, creating the need for improved patient–health care interactions.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Minimally invasive thymectomy for ocular myasthenia gravis (MG) enhanced complete stable remission rates and reduced surgical risks.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options.

Gefurulimab shows significant improvements in myasthenia gravis (MG) symptoms, offering a convenient self-administered treatment option for patients.

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, advocate for improved proactive management of myasthenia gravis (MG) for better patient outcomes.

Thorough eye exams in patients who have myasthenia gravis can detect concurrent autoimmune retinopathy and its complications.

Patients successfully self-administer rozanolixizumab for generalized myasthenia gravis (gmG), preferring manual push delivery over infusion pumps in a phase 3 trial.

Efgartigimod shows promising efficacy over IV immunoglobulin in treating impending myasthenic crisis in patients with myasthenia gravis.

Patients with myasthenia gravis had more COVID-19–related anxieties due to their diagnosis and immunosuppressive therapies.